Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | COMT | P21964 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | IDE | P14735 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | CCR6 | P51684 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21903885 | 0.84 | CDK2 (0.41) | TTRCOMTMEN1NSD2POLB | |
| SCHEMBL7735396 | 0.84 | CDK2 (0.62) | TTRCOMTMEN1NSD2POLB | |
| SCHEMBL5007156 | 0.81 | TTR (0.51) | TTRCOMTMEN1NSD2POLB | |
| SCHEMBL30233642 | 0.80 | TTR (0.75) | TTRCOMTMEN1NSD2POLB | |
| SCHEMBL6242 | 0.80 | TTR (0.75) | TTRCOMTMEN1NSD2POLB | |
| SCHEMBL29363198 | 0.80 | TTR (0.75) | TTRCOMTMEN1NSD2POLB | |
| Hydrochloric Acid SCHEMBL10824889 | 0.79 | TTR (0.50) | TTRCOMTMEN1NSD2POLB | |
| Ammonia Solution, Strong SCHEMBL25312340 | 0.78 | TTR (0.72) | TTRCOMTMEN1NSD2POLB | |
| Ammonia Solution, Strong SCHEMBL10954121 | 0.78 | TTR (0.72) | TTRCOMTMEN1NSD2POLB | |
| Water SCHEMBL242080 | 0.78 | TTR (0.72) | TTRCOMTMEN1NSD2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113227054-B | ROCK kinase inhibitors | 切尔韦洛治疗有限责任公司 | 2025-04-11 | — | — | CN | disclosed |
| EP-3877364-B1 | ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-115951558-A | Photosensitive resin composition containing polysiloxane | 上海玟昕科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3877364-A1 | ROCK KINASE INHIBITORS | Cervello Therapeutics, LLC (US) | 2021-09-15 | — | — | EP | disclosed |
| CN-113227054-A | ROCK kinase inhibitors | 切尔韦洛治疗有限责任公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20200262844-A1 | ROCK KINASE INHIBITORS | CERVELLO THERAPEUTICS, LLC. | 2020-08-20 | — | — | US | disclosed |
| US-10745381-B2 | Substituted isoquinolines and phthalazines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200140412-A1 | ROCK KINASE INHIBITORS | CERVELLO THERAPEUTICS, LLC. | 2020-05-07 | — | — | US | disclosed |
| US-7414063-B2 | Inhibitors of Akt (protein kinase B) | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | ELI LILLY AND COMPANY | 2007-02-22 | — | — | US | disclosed |
| CN-1768040-A | Isoquinoline-5-sulfonic acid amides as inhibitors of AKT (protein kinase B) | LILLY CO ELI (US) | 2006-05-03 | — | — | CN | disclosed |
| EP-1611105-A1 | ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) | ELI LILLY AND COMPANY (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004094386-A1 | ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745381-B2 | Substituted isoquinolines and phthalazines as rock kinase inhibitors | ROCK1, ROCK2, CIT | TTR 4852/4885COMT 1802/4885MEN1 467/4885 |
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | TTR 4855/4885COMT 1290/4885MEN1 455/4885 |
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | AKT1, AKT2, BRAF | TTR 4493/4885COMT 4168/4885MEN1 1215/4885 |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | TTR 4855/4885COMT 1290/4885MEN1 455/4885 |
| US-20200140412-A1 | ROCK KINASE INHIBITORS | ROCK1, ROCK2, RHOA | TTR 4857/4885COMT 2191/4885MEN1 239/4885 |
| US-20200262844-A1 | ROCK KINASE INHIBITORS | ROCK1, ROCK2, RHOA | TTR 4857/4885COMT 2191/4885MEN1 239/4885 |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | ROCK1, ROCK2, CIT | TTR 4855/4885COMT 1290/4885MEN1 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.